UPC vs CPRX vs NKTR vs RARE vs ARWR

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 18. 5x trailing P/E (16. 5x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Catalyst Pharmaceuticals, Inc.

(CPRX) delivered a total return of +546. 3%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: CPRX returned +48. 0% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Catalyst Pharmaceuticals, Inc.

(CPRX) is the lower-risk stock at 0. 84β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 113% more volatile than CPRX relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Catalyst Pharmaceuticals, Inc.

(CPRX) is the more profitable company, earning 36. 4% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43. 8% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 85.

1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Catalyst Pharmaceuticals, Inc.

(CPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CPRX: +48. 0%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: UPC is a small-cap quality compounder stock; CPRX is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.